+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Bristol-Myers Squibb Co (BMY) - Financial and Strategic SWOT Analysis Review

1 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Eli Lilly and Co
  • Johnson & Johnson
  • Merck & Co Inc
  • Novartis AG
  • Sandoz Inc
  • MORE
Bristol-Myers Squibb Co (BMY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

Critical Information Included
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Bristol-Myers Squibb Co (BMS) is a specialty biopharmaceutical company discovers, develops, licenses, manufactures, markets, distributes and sells medicines to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and virology (including hepatitis B, hepatitis C and HIV infection) therapeutic projects. The company offers its products across the world to retail pharmacies, wholesalers, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, Japan and other countries. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

Bristol-Myers Squibb Co Key Recent Developments

Mar 28, 2019 Bristol-Myers Squibb and Concerto HealthAI Announce Strategic Agreement to Broaden Uses of Real-World Evidence and Accelerate Precision Oncology Innovations
Mar 20, 2019 Parker Institute to share pancreatic cancer trial results, microbiome and immunotherapy research, and new CAR-T approaches at AACR 2019
Mar 19, 2019 Bristol-Myers Squibb files investor presentation highlighting significant benefits of pending transaction with Celgene
Mar 01, 2019 BMS faces shareholder opposition to $74bn Celgene acquisition

Key Benefits Include

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Eli Lilly and Co
  • Johnson & Johnson
  • Merck & Co Inc
  • Novartis AG
  • Sandoz Inc
  • MORE
Section 1 - About the Company
  • Bristol-Myers Squibb Co - Key Facts
  • Bristol-Myers Squibb Co - Key Employees
  • Bristol-Myers Squibb Co - Key Employee Biographies
  • Bristol-Myers Squibb Co - Major Products and Services
  • Bristol-Myers Squibb Co - History
  • Bristol-Myers Squibb Co - Company Statement
  • Bristol-Myers Squibb Co - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 – Company Analysis
  • Company Overview
  • Bristol-Myers Squibb Co - Business Description
  • Business Segment: BioPharmaceuticals
  • Overview
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Others
  • Performance
  • Geographical Segment: Rest of the World
  • Performance
  • Geographical Segment: United States
  • Performance
  • R&D Overview
  • Bristol-Myers Squibb Co - Corporate Strategy
  • Bristol-Myers Squibb Co - SWOT Analysis
  • SWOT Analysis - Overview
  • Bristol-Myers Squibb Co - Strengths
  • Bristol-Myers Squibb Co - Weaknesses
  • Bristol-Myers Squibb Co - Opportunities
  • Bristol-Myers Squibb Co - Threats
  • Bristol-Myers Squibb Co - Key Competitors
Section 3 – Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
  • Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
  • Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
  • Bristol-Myers Squibb Co, Recent Deals Summary
Section 5 – Company’s Recent Developments
  • Mar 28, 2019: Bristol-Myers Squibb and Concerto HealthAI Announce Strategic Agreement to Broaden Uses of Real-World Evidence and Accelerate Precision Oncology Innovations
  • Mar 20, 2019: Parker Institute to share pancreatic cancer trial results, microbiome and immunotherapy research, and new CAR-T approaches at AACR 2019
  • Mar 19, 2019: Bristol-Myers Squibb files investor presentation highlighting significant benefits of pending transaction with Celgene
  • Mar 01, 2019: BMS faces shareholder opposition to $74bn Celgene acquisition
  • Feb 28, 2019: Bristol-Myers Squibb issues statement in response to Starboard's letter
  • Feb 27, 2019: Top pharma executives testify before US Senate over high prices
  • Feb 05, 2019: US Senate invites seven pharma majors to testify on price hikes
  • Jan 24, 2019: Bristol-Myers Squibb Reports 2018 Fourth Quarter and Full Year Financial Results
  • Jan 24, 2019: EORTC collaborates with IDDI on ground-breaking statistical method for individualisation of therapy
  • Jan 15, 2019: Inovio's dMAb PD-1 Checkpoint Inhibitors Demonstrate Higher and More Prolonged Expression Compared to Native Pembrolizumab and Nivolumab Sequences In Preclinical Studies
Section 6 – Appendix
  • Methodology
  • Ratio Definitions
  • About the Author
  • Contact Us
  • Disclaimer
List of Tables
  • Bristol-Myers Squibb Co, Key Facts
  • Bristol-Myers Squibb Co, Key Employees
  • Bristol-Myers Squibb Co, Key Employee Biographies
  • Bristol-Myers Squibb Co, Major Products and Services
  • Bristol-Myers Squibb Co, History
  • Bristol-Myers Squibb Co, Subsidiaries
  • Bristol-Myers Squibb Co, Joint Venture
  • Bristol-Myers Squibb Co, Key Competitors
  • Bristol-Myers Squibb Co, Ratios based on current share price
  • Bristol-Myers Squibb Co, Annual Ratios
  • Bristol-Myers Squibb Co, Annual Ratios (Cont...1)
  • Bristol-Myers Squibb Co, Annual Ratios (Cont...2)
  • Bristol-Myers Squibb Co, Interim Ratios
  • Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
  • Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
  • Bristol-Myers Squibb Co, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Bristol-Myers Squibb Co, Performance Chart (2014 - 2018)
  • Bristol-Myers Squibb Co, Ratio Charts
  • Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
  • Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Eli Lilly and Co
  • Abbott Laboratories
  • TESARO Inc
  • Sanofi
  • GlaxoSmithKline Plc
  • Teva Pharmaceutical Industries Ltd
  • Sangui BioTech International Inc
  • Lescarden Inc
  • Theratechnologies Inc
  • Johnson & Johnson
  • Merck & Co Inc
  • Omniox Inc
  • Mylan NV
  • Intercept Pharmaceuticals Inc
  • Allergan Plc
  • Sandoz Inc
  • Novartis AG
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/1290748
Adroll
adroll